Mock Medical Oncology Module 1

A 60-year-old patient with unresectable, limited-stage small cell lung cancer has completed concurrent chemoradiation without experiencing progression.

Which of the following is the most appropriate next step in management?

Consolidation with durvalumab for 2 years or until progression

Correct Incorrect Correct answer

Observation with regular follow-up

Correct Incorrect Correct answer

Additional chemotherapy with a different regimen

Correct Incorrect Correct answer

Radiation therapy boost to the primary tumor site

Correct Incorrect Correct answer

Surgical resection of the primary tumor

Correct Incorrect Correct answer

A 45-year-old non-smoker Filipino woman presents with a lung mass that is initially diagnosed as squamous cell carcinoma on biopsy. However, the pathologist also notes that the tumor has some glandular features.

As part of the diagnostic workup, molecular testing for targetable mutations is being considered.

Which of the following is the most appropriate next step in evaluating this tumor for potential molecular targets?

Perform IHC for ROS-1, EGFR, and ALK to evaluate for potential molecular targets.

Correct Incorrect Correct answer

Perform PCR-based molecular testing for EGFR mutations directly on the biopsy specimen.

Correct Incorrect Correct answer

Perform fluorescence in situ hybridization (FISH) for ALK rearrangements on the biopsy specimen.

Correct Incorrect Correct answer

Perform immunohistochemistry (IHC) for TTF-1, p63, and markers of adenocarcinoma to rule out adenosquamous carcinoma.

Correct Incorrect Correct answer

Perform next-generation sequencing (NGS) on the biopsy specimen to detect multiple mutations simultaneously.

Correct Incorrect Correct answer

What type of lung cancer is characterized by the expression of Delta-like 3 (DLL3)?

Small cell lung cancer (SCLC)

Correct Incorrect Correct answer

Large cell neuroendocrine carcinoma (LCNEC) of the lung

Correct Incorrect Correct answer

Adenocarcinoma of the lung with ALK rearrangements

Correct Incorrect Correct answer

Squamous cell carcinoma of the lung

Correct Incorrect Correct answer

Non-small cell lung cancer (NSCLC) with EGFR mutations

Correct Incorrect Correct answer

Which of the following compounds found in cigarette smoke is considered the most potent and widely recognized carcinogen, particularly due to its role in the formation of DNA adducts leading to mutagenesis?

Polycyclic Aromatic Hydrocarbons (PAHs)

Correct Incorrect Correct answer

Nicotine

Correct Incorrect Correct answer

Carbon Monoxide

Correct Incorrect Correct answer

Tobacco-specific nitrosamines (TSNAs)

Correct Incorrect Correct answer

Acrolein

Correct Incorrect Correct answer

Which of the following substances found in e-cigarette vapour is classified as a known carcinogen?

Formaldehyde

Correct Incorrect Correct answer

Water Vapor

Correct Incorrect Correct answer

Vegetable Glycerin

Correct Incorrect Correct answer

Propylene Glycol

Correct Incorrect Correct answer

Flavouring Agents

Correct Incorrect Correct answer

Based on the findings from a randomised trial involving high-risk male former and current smokers, what was the observed impact of volume-based, low-dose computed tomographic (CT) screening on lung-cancer mortality at 10 years of follow-up?

A 24% reduction in lung-cancer mortality in the screening group compared to the control group

Correct Incorrect Correct answer

No significant difference in lung-cancer mortality between the screening and control groups

Correct Incorrect Correct answer

A 12% increase in lung-cancer mortality in the screening group compared to the control group

Correct Incorrect Correct answer

A 52% reduction in lung-cancer mortality in the screening group compared to the control group

Correct Incorrect Correct answer

Lung-cancer mortality was unaffected by adherence to CT screening protocols

Correct Incorrect Correct answer

What is the mechanism of action of Ipilimumab?

A fully human monoclonal antibody that binds to cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)

Correct Incorrect Correct answer

A humanized monoclonal antibody that binds to tumor necrosis factor-alpha (TNF-alpha)

Correct Incorrect Correct answer

A monoclonal antibody that interferes with the human epidermal growth factor receptor 2 (HER2/neu)

Correct Incorrect Correct answer

A recombinant humanised monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A)

Correct Incorrect Correct answer

A chimeric monoclonal antibody that binds to epidermal growth factor receptor (EGFR)

Correct Incorrect Correct answer

What is the most common side effect of Osimertinib?

Diarrhoea

Correct Incorrect Correct answer

Constipation

Correct Incorrect Correct answer

Interstitial lung disease

Correct Incorrect Correct answer

Fatigue

Correct Incorrect Correct answer

Cardiotoxicity with QT prolongation

Correct Incorrect Correct answer

A 65 year old man has been newly diagnosed with advanced unresectable (non-epithelioid) malignant pleural mesothelioma.

Which combination of treatment is likely to increase his overall survival?

Bevacizumab, Cisplatin and Pemetrexed.

Correct Incorrect Correct answer

Nivolumab and Ipilimumab

Correct Incorrect Correct answer

Bevacizumab, Nivolumab and Pemetrexed

Correct Incorrect Correct answer

Bevacizumab and Pemetrexed

Correct Incorrect Correct answer

Gemcitabine and Carboplatin.

Correct Incorrect Correct answer

A 60 year old Chinese woman who is a lifelong non-smoker presents with 3 months history of back pain. On staging CT she is found to have a large right lower lobe mass with evidence of bony metastases.
The biopsy of this mass shows a poorly differentiated adenocarcinoma.

What would be the most likely molecular mutation to be present in this lady and the best treatment option?

EGFR mutation and Osimertinib

Correct Incorrect Correct answer

KIT mutation and Imatinib

Correct Incorrect Correct answer

BRAF mutation and Dabrafenib

Correct Incorrect Correct answer

KRAS mutation and Erlotinib

Correct Incorrect Correct answer

Oestrogen receptor and Aromatase Inhibitor

Correct Incorrect Correct answer

Denosumab is a fully human monoclonal antibody that is recognized to be effective in the prevention of skeletal-related events in patients with bone metastases from solid tumors.

What is the main advantage of this agent compared to bisphosphonates?

no dose adjustment required for patients with renal impairment.

Correct Incorrect Correct answer

lower risk of hypocalcemia

Correct Incorrect Correct answer

does not cause osteonecrosis of the jaw

Correct Incorrect Correct answer

can be administered once monthly rather than daily.

Correct Incorrect Correct answer

lesser risk for skin infection

Correct Incorrect Correct answer

A 40 year old woman, usually fit and well presents with a month’s history of abdominal pains associated with malaena and haemetemesis. Her abdominal CT scan shows a 13cm tumour arising from the duodenal wall and a further 4cm liver lesion in segment 8. The history is consistent with CD117 positive gastrointestinal stromal tumour of duodenum.

Given this clinical scenario, which of the following molecular marker is most likely to be mutated?

KIT

Correct Incorrect Correct answer

BRAF

Correct Incorrect Correct answer

KRAS

Correct Incorrect Correct answer

EGFR

Correct Incorrect Correct answer

PDGFRA

Correct Incorrect Correct answer

A 16 year old man with neuroblastoma is having treatment with chemotherapy.

If a leakage of the drug occurs, which one of the following chemotherapy drugs is most likely to cause vesicant extravasation?

vincristine

Correct Incorrect Correct answer

cyclophosphamide

Correct Incorrect Correct answer

cytosine arabinoside

Correct Incorrect Correct answer

ifosfamide

Correct Incorrect Correct answer

methotrexate

Correct Incorrect Correct answer

A 55-year-old woman with a history of non-small cell lung cancer is undergoing treatment with immune checkpoint inhibitors (ICIs). After starting therapy, her clinical condition rapidly deteriorates over 8 weeks, with significant increases in tumor size and the appearance of new metastatic lesions on imaging.

Which of the following clinical features would make hyperprogressive disease (HPD) the most likely diagnosis in this patient?

Rapid clinical deterioration and a marked increase in tumor burden shortly after initiating ICI therapy.

Correct Incorrect Correct answer

A gradual increase in tumor size consistent with the expected progression of her underlying cancer.

Correct Incorrect Correct answer

Rapid clinical deterioration and a marked increase in tumor burden shortly after stopping ICI therapy.

Correct Incorrect Correct answer

Stabilization of tumor size with intermittent periods of slight increase in tumor burden.

Correct Incorrect Correct answer

Development of new, treatment-responsive lesions without an overall increase in tumor burden.

Correct Incorrect Correct answer

In a previously untreated advanced ALK-positive non-small cell lung cancer, which of the following targeted cancer therapy would be most effective?

Lorlatinib

Correct Incorrect Correct answer

Crizotinib

Correct Incorrect Correct answer

Erlotinib

Correct Incorrect Correct answer

Sunitinib

Correct Incorrect Correct answer

Dabrafenib

Correct Incorrect Correct answer

Which of the following is a known side effect of Lapatinib?

Palmar-plantar erythrodysaesthesia

Correct Incorrect Correct answer

Hot flushes

Correct Incorrect Correct answer

Vaginal dryness

Correct Incorrect Correct answer

Osteoporosis

Correct Incorrect Correct answer

Adverse lipid profile

Correct Incorrect Correct answer

A 63-year-old man has just been diagnosed with advanced non-small cell lung cancer with brain metastases.

Further immunohistochemistry testing reveals the following:

ALK negative
BRAF negative
EGFR negative
RET fusion positive
PD-L1 negative
ROS1 negative

Which of the following treatments would he most likely respond to?

Selpercatinib

Correct Incorrect Correct answer

Osimertinib

Correct Incorrect Correct answer

Pembrolizumab

Correct Incorrect Correct answer

Alectinib

Correct Incorrect Correct answer

Crizotinib

Correct Incorrect Correct answer

In the management of stage IV non-small cell lung cancer (NSCLC), why is next-generation sequencing (NGS) particularly important?

To identify actionable genetic mutations for targeted therapy

Correct Incorrect Correct answer

To confirm the histopathological diagnosis of NSCLC

Correct Incorrect Correct answer

To determine the need for surgical resection

Correct Incorrect Correct answer

To assess the patient's suitability for whole brain radiation therapy

Correct Incorrect Correct answer

To evaluate the effectiveness of traditional chemotherapy regimens

Correct Incorrect Correct answer

A 63-year-old male with a 40-pack-year smoking history presents with unintentional weight loss, persistent cough, and shortness of breath. A biopsy from a bronchoscopy confirms metastatic nonsquamous non-small cell lung cancer (NSCLC) without EGFR or ALK mutations. PD-L1 expression is noted to be 40% on tumor cells.

What would be the most appropriate first-line treatment for this patient?

Pemetrexed and a platinum-based drug combined with pembrolizumab

Correct Incorrect Correct answer

Pemetrexed and a platinum-based drug without pembrolizumab

Correct Incorrect Correct answer

Pembrolizumab monotherapy

Correct Incorrect Correct answer

Palliative radiotherapy only

Correct Incorrect Correct answer

Targeted therapy based on EGFR mutations

Correct Incorrect Correct answer

What is the most effect and optimal first-line treatment for patients with EGFR (exon 19 deletion or L858R mutation) mutated advanced NSCLC?

Osimertinib plus chemotherapy (Pemetrexed plus Cisplatin or Carboplatin)

Correct Incorrect Correct answer

Osimertinib monotherapy

Correct Incorrect Correct answer

Platinum–pemetrexed chemotherapy alone

Correct Incorrect Correct answer

Afatinib monotherapy

Correct Incorrect Correct answer

Amivantamab plus lazertinib

Correct Incorrect Correct answer

A 55-year-old male patient with a history of smoking presents to the oncology clinic with a recent diagnosis of resectable stage IllA non-small-cell lung cancer (NSCLC).

He is being considered for peri-operative therapy.

Which of the following therapeutic strategies is most likely to improve his event-free survival?

Neoadjuvant chemotherapy alone followed by surgery

Correct Incorrect Correct answer

Neoadjuvant pembrolizumab plus chemotherapy followed by surgery and adjuvant pembrolizumab

Correct Incorrect Correct answer

Neoadjuvant pembrolizumab alone followed by surgery

Correct Incorrect Correct answer

Surgery followed by adjuvant pembrolizumab plus chemotherapy

Correct Incorrect Correct answer

Surgery followed by adjuvant chemotherapy alone

Correct Incorrect Correct answer

A 50-year-old male ex-smoker presents to your clinic with 3 months history of persistent cough and unexplained weight loss. A chest X-ray requested by his GP last week suggested a possible lesion in the right upper lobe. A CT scan confirms the presence of a 4 cm right upper lobe lesion which appears highly suspicious for a primary lung malignancy.

He was then referred for a PET-CT for further staging.

His PET scan shows a strongly avid lesion in the right upper lobe but without any lymph node or metastatic disease.

Functionally, he has an ECOG score of 1 with excellent exercise tolerance.

He then proceeds to curative surgery with a right upper lobectomy.

Lung histology confirms the diagnosis of non-small cell lung cancer with the following immunohistochemistry: ALK positive, EGFR negative, RET negative, PD-L1 <1%

Following surgery, which of the following interventions would likely improve his survival?

Adjuvant Alectinib

Correct Incorrect Correct answer

Adjuvant Selpercatinib

Correct Incorrect Correct answer

Adjuvant Platinum-based chemotherapy

Correct Incorrect Correct answer

Adjuvant Pembrolizumab

Correct Incorrect Correct answer

Adjuvant Osimertinib

Correct Incorrect Correct answer

A 75-year-old female with a history of severe COPD presents with a newly diagnosed 2 cm peripheral non-small cell lung cancer (NSCLC) in the right lower lobe.

Pulmonary function tests reveal a FEV1 of 40% predicted, and the patient is deemed a high-risk candidate for surgical intervention.

What is the most appropriate management option for this patient, considering her underlying comorbidities and the stage of her lung cancer?

Stereotactic ablative radiotherapy (SABR)

Correct Incorrect Correct answer

Video-assisted thoracoscopic surgery (VATS) lobectomy

Correct Incorrect Correct answer

Open lobectomy

Correct Incorrect Correct answer

Palliative care only

Correct Incorrect Correct answer

Chemotherapy

Correct Incorrect Correct answer

Based on a study that evaluated the efficacy of adjuvant atezolizumab after platinum-based chemotherapy in early-stage NSCLC, what was the impact of atezolizumab on disease-free survival in the stage II–IIIA population whose tumors expressed PD-L1 on 1% or more of tumor cells?

Atezolizumab significantly increased disease-free survival compared to best supportive care in patients with PD-L1-positive tumors.

Correct Incorrect Correct answer

Atezolizumab significantly decreased disease-free survival compared to best supportive care in patients with PD-L1-positive tumors.

Correct Incorrect Correct answer

Atezolizumab showed no significant difference in disease-free survival compared to best supportive care.

Correct Incorrect Correct answer

Atezolizumab significantly increased disease-free survival in all patients regardless of PD-L1 expression.

Correct Incorrect Correct answer

Atezolizumab significantly increased disease-free survival only in patients with PD-L1-negative tumors.

Correct Incorrect Correct answer

A 68-year-old male smoker presents with a persistent cough and unintentional weight loss. A chest radiograph reveals a suspicious 3 cm mass in the right upper lobe.

Further evaluation with CT scan shows no evidence of mediastinal lymphadenopathy.

A CT guided lung biopsy of the right upper lobe mass has been confirmed as TTF1 positive lung adenocarcinoma.

The next best step in the management of this patient to assess the extent of disease would be:

Positron Emission Tomography-Computed Tomography (PET-CT)

Correct Incorrect Correct answer

Immediate surgical resection

Correct Incorrect Correct answer

Bronchoscopy with biopsy

Correct Incorrect Correct answer

Mediastinoscopy with lymph node sampling

Correct Incorrect Correct answer

Refer for whole body CT scan

Correct Incorrect Correct answer

Nivolumab is a fully human antibody that has been shown to be effective in the treatment of ipilimumab-refractory melanoma.

Which of the following is the target receptor for this agent?

PD-1

Correct Incorrect Correct answer

CTLA-4

Correct Incorrect Correct answer

CD52

Correct Incorrect Correct answer

CD20

Correct Incorrect Correct answer

CD28

Correct Incorrect Correct answer

Which of the following is NOT a recognized risk factor for cutaneous melanoma?

Dark skin

Correct Incorrect Correct answer

Blonde hair

Correct Incorrect Correct answer

Fair skin

Correct Incorrect Correct answer

Immunosuppression

Correct Incorrect Correct answer

Presence of dysplastic naevi

Correct Incorrect Correct answer

Adoptive cell therapy with Tumour Infiltrating Lymphocytes (TILs) has shown promising results in the treatment of which malignancy?

Metastatic melanoma

Correct Incorrect Correct answer

Lung cancer

Correct Incorrect Correct answer

Metastatic colorectal cancer

Correct Incorrect Correct answer

Prostate cancer

Correct Incorrect Correct answer

Non-Hodgkin's Lymphoma

Correct Incorrect Correct answer

Which of the following mutations is primarily associated with the molecular drivers of cutaneous melanoma?

BRAF

Correct Incorrect Correct answer

GNAQ

Correct Incorrect Correct answer

GNA11

Correct Incorrect Correct answer

G proteins

Correct Incorrect Correct answer

SF3B1

Correct Incorrect Correct answer

Which of the following oral kinase inhibitors is correctly matched with its target receptor?

Dabrafenib – BRAF inhibitor

Correct Incorrect Correct answer

Vemurafenib – MEK inhibitor

Correct Incorrect Correct answer

Cobimetinib – BRAF inhibitor

Correct Incorrect Correct answer

Encorafenib – MEK inhibitor

Correct Incorrect Correct answer

Trametinib – BRAF inhibitor

Correct Incorrect Correct answer

A 58-year-old male presents to the oncology clinic with a confirmed diagnosis of metastatic melanoma. The patient has a history of a pigmented lesion on his back, which was surgically excised two years ago. He recently noted the development of new, painless, subcutaneous nodules on his abdomen and underwent a biopsy. Histopathological examination revealed malignant melanoma, and subsequent staging workup including a PET-CT scan confirmed multiple metastatic lesions in the liver and lungs.

The patient’s medical history is significant for hypertension, which is well-controlled on medication, and he has no known drug allergies. He has a family history of non-melanoma skin cancer but no known family history of melanoma or other hereditary cancers. The patient is a retired teacher, lives with his wife, and is a non-smoker with occasional alcohol use.

Molecular testing of the melanoma tissue did not detect a BRAF mutation; thus, the melanoma is classified as BRAF -ve. His performance status is good, and he expresses a willingness to undergo treatment.

Considering the patient’s BRAF mutation-negative status, which of the following treatment options is most appropriate for this patient?

Combination of PD-1 inhibitor and BRAF inhibitor (BRAFi)

Correct Incorrect Correct answer

MEK inhibitor (MEKi) monotherapy

Correct Incorrect Correct answer

Combination of CTLA-4 and PD-1 inhibitors

Correct Incorrect Correct answer

Combination of BRAF inhibitor and MEK inhibitor (BRAFi + MEKi)

Correct Incorrect Correct answer

Combination of PD-1 inhibitor and MEK inhibitor

Correct Incorrect Correct answer

A 45-year-old woman with metastatic melanoma has been started on a combination therapy of dabrafenib and trametinib. She has a past medical history of hypothyroidism, which is well controlled with levothyroxine. She has no known drug allergies. After initiating treatment, she returns to the clinic for a follow-up visit. During the evaluation, she reports experiencing a new side effect since starting the therapy.

Based on the adverse events profile for the combination of dabrafenib and trametinib in the treatment of metastatic melanoma, which of the following is the most common side effect that she is likely to report?

Fever

Correct Incorrect Correct answer

Hand-foot syndrome

Correct Incorrect Correct answer

Cutaneous squamous-cell carcinoma

Correct Incorrect Correct answer

Decrease in ejection fraction

Correct Incorrect Correct answer

Dermatitis acneiform

Correct Incorrect Correct answer

A 63-year-old female with advanced melanoma, refractory to initial anti–PD-1 therapy, presents for consideration of further treatment options. She has a performance status of 1 and her serum lactate dehydrogenase (LDH) levels are within normal limits. Her melanoma does not harbor a BRAF V600 mutation. She participated in a phase 3, multicenter, randomized trial where she was assigned to receive T-cell infusion (TIL) therapy as a second-line treatment. The patient is interested in understanding the efficacy of her assigned treatment compared to traditional therapies such as ipilimumab.

Which of the following statements best reflects the findings related to progression-free survival (PFS) for TIL therapy?

The progression-free survival was more than twice as long in the TIL group compared to the ipilimumab group.

Correct Incorrect Correct answer

TIL therapy did not significantly affect the progression-free survival when compared to ipilimumab.

Correct Incorrect Correct answer

TIL therapy and ipilimumab showed similar progression-free survival rates at the 6-month mark post-treatment.

Correct Incorrect Correct answer

TIL therapy showed a 30% lower progression-free survival rate compared to ipilimumab at 6 months.

Correct Incorrect Correct answer

Progression-free survival with TIL therapy was less than that of ipilimumab treatment.

Correct Incorrect Correct answer

Amivantamab has an established role in the treatment of which type of lung cancer?

Metastatic NSCLC with EGFR exon 20 insertion mutations

Correct Incorrect Correct answer

Metastatic NSCLC with ALK rearrangement

Correct Incorrect Correct answer

Metastatic NSCLC with wild-type EGFR

Correct Incorrect Correct answer

Metastatic NSCLC with the EGFR T790M resistance mutation

Correct Incorrect Correct answer

What is the primary role of neoadjuvant nivolumab plus ipilimumab in the management of resectable stage III melanoma?

It is administered before surgery to induce tumour regression, eradicate micrometastatic disease, and improve event-free survival.

Correct Incorrect Correct answer

It is administered after complete surgical resection as standard adjuvant therapy for all patients with stage III melanoma.

Correct Incorrect Correct answer

It is used to downstage unresectable melanoma to allow palliative surgery.

Correct Incorrect Correct answer

It replaces the need for complete lymph node dissection in patients with clinically node-positive disease.

Correct Incorrect Correct answer

It is indicated only in patients with BRAF V600-mutant melanoma.

Correct Incorrect Correct answer

A 62-year-old man with a 40-pack-year smoking history is diagnosed with treatment-naïve stage IIIB squamous non-small cell lung cancer (NSCLC). Molecular testing confirms no EGFR or ALK alterations, and his PD-L1 tumour proportion score (TPS) is <1%. His ECOG performance status is 1. He asks about a novel bispecific antibody he has read about that targets both PD-1 and VEGF.

Based on the HARMONi-6 trial, which of the following statements is most accurate regarding ivonescimab plus chemotherapy compared with tislelizumab plus chemotherapy in this setting?

Ivonescimab plus chemotherapy improved overall survival but was associated with a higher rate of grade ≥3 treatment-related toxicity, including proteinuria and haemorrhage

Correct Incorrect Correct answer

Overall survival benefit was confined to patients with PD-L1 TPS ≥1%

Correct Incorrect Correct answer

The addition of ivonescimab significantly improved overall survival with a similar rate of grade ≥3 treatment-related toxicity

Correct Incorrect Correct answer

Severe pulmonary haemorrhage was markedly increased in patients with central tumours, precluding its use in squamous histology

Correct Incorrect Correct answer

The trial established ivonescimab as superior to pembrolizumab-based chemo-immunotherapy

Correct Incorrect Correct answer

Average score
Your score

Mock Medical Oncology Module 1

Quiz Summary

Information

Results

Results

Categories

1. Question

2. Question

3. Question

4. Question

5. Question

6. Question

7. Question

8. Question

9. Question

10. Question

11. Question

12. Question

13. Question

14. Question

15. Question

16. Question

17. Question

18. Question

19. Question

20. Question

21. Question

22. Question

23. Question

24. Question

25. Question

26. Question

27. Question

28. Question

29. Question

30. Question

31. Question

32. Question

33. Question

34. Question

35. Question

36. Question